Continuum Advisory’s NovoCure NVCR Stock Holding History

Continuum Advisory’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50	Closed	-$829	–	1932
2024 Q3	$829	Buy	+50	New	+$907	﹤0.01%	1666

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Continuum Advisory's NVCR Position: Q4 2024 in Review

Continuum Advisory sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 50 shares — an estimated $829 sold.

Continuum Advisory first reported a position in NVCR in Q3 2024 and held it in 1 quarter. The position peaked at $829 in Q3 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

Continuum Advisory reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
Continuum Advisory sold 50 NovoCure shares in Q4 2024, an estimated $829.
Continuum Advisory first reported a position in NovoCure in Q3 2024 and held it in 1 quarter.
Continuum Advisory's NovoCure position peaked at $829 in Q3 2024.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Continuum Advisory's 13F filing for Q4 2024, filed 18 Feb 2025.